BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 38612480)

  • 1. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Expression Patterns Associated with Survival in Glioblastoma.
    Morrison C; Weterings E; Gravbrot N; Hammer M; Weinand M; Sanan A; Pandey R; Mahadevan D; Stea B
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression Profile Analysis Identifies a Novel Five-Gene Signature to Improve Prognosis Prediction of Glioblastoma.
    Yin W; Tang G; Zhou Q; Cao Y; Li H; Fu X; Wu Z; Jiang X
    Front Genet; 2019; 10():419. PubMed ID: 31130992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
    Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
    J Neurosurg; 2019 Jan; 132(1):168-179. PubMed ID: 30641835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor.
    Zuccarini M; Giuliani P; Ziberi S; Carluccio M; Iorio PD; Caciagli F; Ciccarelli R
    Genes (Basel); 2018 Feb; 9(2):. PubMed ID: 29462960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting WNT Signaling for Multifaceted Glioblastoma Therapy.
    McCord M; Mukouyama YS; Gilbert MR; Jackson S
    Front Cell Neurosci; 2017; 11():318. PubMed ID: 29081735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NovoTTF: where to go from here?
    Cloughesy TF; Lassman AB
    Neuro Oncol; 2017 May; 19(5):605-608. PubMed ID: 28453750
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.